NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...
Vast's bold ambition: developing Haven-1, the first commercial space station. Learn about their successful primary structure qualification proof test.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback